Emergent Technologies, Inc. announced today that its portfolio company,
Receptor Logic, has entered into an exclusive License Agreement with
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for autoimmune diseases,
asthma and allergic diseases, and cancer. The agreement gives Xencor the
exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm)
monoclonal antibody against the target NY-ESO1, developed by Receptor
Logic, for cancer treatment.
“Our expertise in cancer target identification, when coupled with our
development of TCRm monoclonal antibodies to cancer targets, provides a
powerful pipeline for immuno-oncology drug development,” said Chief
Scientist William Hildebrand, Ph.D. “By identifying HLA/cancer antigen
targets and making TCRm monoclonal antibodies to these targets, we
provide industry partners with a steady stream of more personalized
cancer therapeutics.”
“This agreement with Xencor reflects the significant value of our
platform as we continue to advance into personalized medicine,” said
Thomas Harlan, CEO of Receptor Logic and its related company, Pure MHC.
“We‘re excited to provide one of our TCRm antibodies to Xencor to assist
the company in its cancer therapeutic development efforts.”
About Receptor Logic, Inc. and Pure MHC, LLC
Pure MHC, LLC, the market facing entity for the Receptor Logic TCRm
technology, is an immunology company focused on MHC-based diagnostics
and therapeutics providing novel solutions for the treatment of
infectious diseases and cancers. Pure MHC and Receptor Logic were formed
and are managed by Emergent Technologies, Inc.
About Emergent Technologies, Inc.
Austin, TX based Emergent Technologies, Inc. (Emergent) is a leading
innovation solutions company that identifies, manages, develops and
partners to turn game-changing scientific discoveries into market-driven
products. Emergent's diverse business and technical team uses its unique
innovation process to transform scientific breakthroughs into technology
platforms with multiple applications, maximizing the value of promising
ideas and underutilized intellectual properties without the risk
associated with commercial development. The company applies its
experience and expertise to provide investors, entrepreneurs, start-up
companies and industry partners’ access to innovative solutions to
advance initiatives and protect and grow core businesses with novel,
differentiating technology. For more information, visit www.emergenttechnologies.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160112005568/en/
Copyright Business Wire 2016